Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cellbased competition assays employing the native uPAR ligand
Introduction
The plasminogen activation system (PAS) plays a central role in a variety of tissue remodelling processes including tumour invasion and metastasis. 1, 2 Metastasis has been clinically correlated with upregulation of the PAS in multiple tumour types [3] [4] [5] [6] and at least two PAS components are considered as promising targets for developing novel anti-cancer/metastasis therapeutics. [7] [8] [9] In its simplest form, the PAS comprises the serine protease urokinase-type plasminogen activator (uPA), its cognate GPIanchored cell surface-bound receptor (uPAR) and two endogenous serpins; plasminogen activator inhibitor 1 (PAI-1) and plasminogen activator inhibitor 2 (PAI-2). Activation of uPA upon binding to uPAR leads to cleavage of cell surface-associated plasminogen to reveal the broad spectrum serine protease plasmin. Localisation of plasmin activity on cell surfaces at the leading edge of migrating cells provides focussed activation of downstream extracellular zymogens (e.g. proelastases, procollagenases and prostromelysins) and latent growth factors and together these lead to directional pericellular proteolysis and remodelling of the local extracellular environment -key events required during metastasis. 10 A secondary function of the PAS is to activate further cell migration and proliferation signalling via multimeric complexes involving uPAR, transmembrane integrins and vitronectin. [11] [12] [13] The two principle strategies that have been explored for dampening PAS activity with the goal of producing new anti-cancer leads include: (1) inhibitors of the serine protease domain of uPA and (2) antagonists of the uPA:uPAR interaction. Several structural classes of uPA inhibitors have been identified and selected analogues have undergone preclinical evaluation as non-cytotoxic antitumour/metastasis drugs. 14 An orally active uPA inhibitor (MESUPRON®) being developed by Wilex AG (Germany) is currently undergoing phase II trials in patients with breast and pancreatic cancers (http://www.wilex.de/R&D/Mesupron.htm).
The uPA-binding site presented by uPAR is a relatively large hydrophobic cavity (25 Å across, 14 Å deep). 15 Residues Asn 22 -Trp 31 located on a β-hairpin loop of the amino-terminal fragment (ATF) of uPA bury deeply into the cavity giving rise to a high affinity interaction (K D ~ 0.2 nM). 16, 17 Tyr 24 is a major contributor to high affinity as it is located at the tip of the β-hairpin and interacts with all three uPAR domains (DI-DIII). 17, 18 Many of the known uPAR antagonists specifically target the hydrophobic cavity, with reported examples including linear 19 and cyclic 20 peptides and fusion proteins bearing the uPAR binding fragment of uPA. 21 A limited number (five in total) of small molecule non-peptidic uPAR antagonists have also been described. 22 Other anti-uPAR strategies that have been explored include the use of monoclonal antibodies 23 and siRNA. Schering's peptidomimetic derivative 1 (IC 50 = 0.8 nM) 25 and Chiron's CHIR11509 2 (IC 50 = 33 nM). 26 Due to their high potencies, small size and synthetic accessibility compounds 1 and 2 appear to represent useful pharmacological tools for probing the role of the PAS in metastasis.
The IC 50 value for 1 was reportedly determined in a cell-based radioligand competition binding assay While both 1 and 2 are clearly potent antagonists of labelled uPA fragments it was noted that neither compound had to date been tested for their ability to compete with the native uPAR ligand (high molecular weight uPA: HMW-uPA) for uPAR binding, or for their functional effects on plasminogen activation in physiologically relevant cellular settings where the native ligand is present. Such experiments are essential for uPAR antagonists being considered as anti-cancer/metastasis leads since inhibition of uPA activation and downstream pericellular proteolysis is ultimately the effect required for reducing tumour invasion and metastasis in vivo. This paper describes two new syntheses for 1 and 2 and reports the important finding that in physiologically relevant competition cell-based assays using HMW-uPA both compounds are poor uPAR antagonists and show only minimal inhibition of uPA activity at high (µM) concentrations.
Chemistry
Syntheses of 1 and 2 are described in the patent literature but few experimental details and no compound characterisations were provided. 25, 26 The reported method for preparing 1 and various analogues made use of Fmoc-based solid phase synthesis protocols on Sasrin resin. We now report the synthesis and characterisation of 1 using a solution phase peptide synthesis strategy starting from the commercially available 3'-aminobiphenyl-4-carboxylic acid 3 (Scheme 1). Intitial attempts to produce N-Boc-3'-aminobiphenyl-4-carboxylic acid 4 from 3 under standard conditions using Boc-anhydride (Boc 2 O) proved surprisingly difficult (yields < 70%) but it was found that very high yields (>99%) of 4 could be obtained when catalytic I 2 was added to reactions.
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The carboxylic acid 4 was coupled to L-Phe-OMe.HCl using O-benzotriazole-N,N,N',N'-tetramethyluronium-hexafluoro-phosphate (HBTU) and diisopropylethylamine (DIPEA) in DMF to produce 5 in 79-88% yield. The N-Boc group was removed from 5 by stirring with neat trifluoroacetic acid (TFA) in the presence of p-cresol as cation scavenger. The deprotected crude product was coupled to Boc-L-Trp-OH using HBTU and DIPEA in DMF to afford 6 in 53-65% yield. Boc-deprotection of 6 (neat TFA/pcresol) followed by acetylation with acetic anhydride and hydrolysis of the methyl ester (LiOH/THF/H 2 O) provided 1 in 90-95% yield over the final three steps. A new unambiguous mixed solid/solution phase synthesis of 2 based on the submonomer method is now reported (Scheme 2).
Rink amide AM resin bearing an Fmoc-protected amine was deprotected using 20% piperidine in 
Results
Phorbol 12-myristate-13-acetate (PMA) is known to induce high expression levels of unoccupied cell surface uPAR receptors in monocyte-like U-937 leukemia cells without a corresponding increase in uPA expression. confirmed that PMA stimulated U-937 cells express low levels of endogenous receptor-bound uPA.
The rate of increase in fluorescence was found to be significantly higher (indicating higher cell-bound uPA activity) in the presence of 40 nM exogenous HMW-uPA ( Figure 1B , shaded squares). The assay was subsequently extended to a competition format to determine the IC 50 values of uPA inhibition by antagonists (see Figure 3 ) and in all assays 40 nM exogenous HMW-uPA was added to enhance cell surface-bound uPA activity and increase sensitivity. 
Discussion and Conclusions
In addition to the hydrophobic cavity used to engage uPA there exists a second well characterised protein-protein interaction site on uPAR which binds to the somatomedin B (SMB) domain of matrix embedded vitronectin.
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The uPAR:vitronectin interaction is implicated in cell migration processes such as, for example, cytoskeletal rearrangements 37 and remodelling of focal adhesion sites. It was noted that the potencies of 1 and 2 had only previously been measured using radioligand binding assays employing labelled uPAR-binding uPA fragments as the competing ligands in place of uPAR's native ligand HMW-uPA. 25, 26 As a precautionary step before proceeding to further pharmacological investigations with 1 and 2 we sought to confirm that both compounds retained their high potencies in physiologically relevant cell-based competition assays with the native ligand HMWuPA. A semi-quantitative competition flow cytometry assay using uPAR-expressing U-937 cells and a quantitative U-937 cell-based fluorescence assay were used for this purpose. Access to 1 and 2 was afforded through two simple new syntheses.
Compound 1 was found to show no antagonist effects at 100 µM in the flow cytometry assay and only weak inhibition of cell-surface uPA activity in the fluorescence assay (IC 50 > 100 µM). Compound 2 was shown to be a weak uPAR antagonist at concentrations of 10 µM and 100µM and a weak inhibitor of cell-surface uPA activity (IC 50 > 100 µM). Nanomolar concentrations of positive controls (antiuPAR MAb and chloromethylketone-inactivated HMW-uPA) antagonised HMW-uPA binding and inhibited cell surface uPA activity under the same assay conditions. These results are in direct contrast to the high antagonist potencies reported for 1 and 2 from the competition assays using labelled uPA fragments. 25, 26 One possible explanation for the conflicting results arises from the fact that the uPA fragments with bulky groups (e.g. iodine) greatly reduces uPA's affinity for uPAR. 41, 42 Given this and the fact that data comparing the uPAR binding affinity of the were analysed for purity using a 4.6 x 250mm 5 µM Phenomenex Luna C18 column on a Shimadzu CLASS-LC10 VP HPLC system run at 1 mL/min with UV detection at 254 nm. Manual solid-phase peptide synthesis was performed in a Peptides International water-jacketed reaction vessel using a St. (multiplet) and bs (broad singlet) are used throughout.
3'-[[(1,1-dimethylethoxy)carbonyl]amino][1,1'-biphenyl]-4-carboxylic acid (4)
3'-aminobiphenyl-4-carboxylic acid 3 (1.7 g, 6.8 mmol) was covered with dry MeOH (6.8 mL) and stirred. A solution of I 2 (170 mg, 0.68 mmol) and di-tert-butyl dicarbonate (1.48 g, 6.8 mmol) was formed in a separate vessel using a minimal volume of dry MeOH and added to the stirred mixture.
DIPEA (1.186 mL, 6.8 mmol) was added dropwise to the stirred mixture, producing a solution that was 
3'-[N-[(1,1-dimethylethoxy)carbonyl]-L-tryptophylamino][1,1'-biphenyl]-4-carbonyl-Lphenylalanine methyl ester (6).
Compound 5 
3'-(N-acetyl-L-tryptophyl-amino)(1,1'-biphenyl)-4-carbonyl-L-phenylalanine (1).
Compound 6 
2-[N-[2-amino-2-oxoethyl]-2-[N-(naphthalen-2-yl)-2-(prop-2-ynylamino)acetamido]-acetamido]acetic acid trifluoroacetate (7).
Rink amide AM resin (2 g, 0.63 mmol/g) was shaken in a 45 mL solid-phase peptide synthesis vessel with 20% piperidine in CH 2 Cl 2 (10 mL) for 20 min before draining and washing with CH 2 Cl 2 (3 x 15 mL) and DMF (2 x 15 mL). The resin was reswollen with CH 2 Cl 2 (15 mL). Bromoacetic acid (700 mg, 5 mmol) was combined with DCC (1.032 g, 5 mmol) in NMP (5 mL) and CH 2 Cl 2 (10 mL). DMAP (36.6 mg, 0.3 mmol) was added to the drained resin followed by the bromoacetic acid/DCC solution.
The mixture was shaken for 1 h at rt before draining and washing with CH 2 Cl 2 (3 x 15 mL), DMF (2 x 15 mL) and isopropanol (2 x 15 mL). The resin was then dried in vacuo. The dry resin was reswollen in DMSO (24 mL) and drained before a solution of H 2 N-Gly-O and CH 2 Cl 2 (6 x 36 mL). The resin was reswollen with CH 2 Cl 2 (36 mL). Bromoacetic acid (700 mg, 5 mmol) was combined with DCC (1.032 g, 5 mmol) in NMP (5 mL) and CH 2 Cl 2 (10 mL). DMAP (36.6 mg, 0.3 mmol) was added to the drained resin followed by the bromoacetic acid solution. The mixture was shaken for 1 h at rt before draining and washing with CH 2 Cl 2 (6 x 36 mL) and DMF (6 x 36 mL).
The resin was reswollen with DMSO (24 mL) and drained before a solution of propargylamine (272 mg, 4.96 mmol) in DMSO (30 mL) was added. The mixture was shaken at 45 o C for 4 h before draining and washing with DMF (6 x 36 mL) and CH 2 Cl 2 (6 x 36 mL). The resin was then dried in vacuo before treating with a mixture of 95% TFA:2.5% water:2.5% TIPS (36 mL) and cleaved for 1 h at rt. After filtering into a collecting vessel the filtrate was concentrated in vacuo and the residue taken up in DMSO (2 mL) and purified by preparative rp-HPLC using a gradient from 100% solvent A 
Cell Culture.
Human monocyte-like U-937 cells were used for all assays (American Tissue Culture Centre, USA).
Cells were maintained in culture at 37 °C in a humidified incubator containing 5% CO 2 (Thermo Scientific) using pre-warmed RPMI 1640 media supplemented with 2 mM L-glutamine and 5% foetal calf serum (FCS, heat inactivated). Cells were passaged every 3-4 days to maintain a population > 1 x 10 6 cells.mL 
Preparation of i-uPA.
100 µL HMW-uPA (1 mg.mL -1 , 19 µM in distilled water) was reacted with Glu-Gly-Arg-chloromethyl ketone 100 µL (1 mM in distilled water) for 24 h at 4 °C to form i-uPA. 34 Absence of activity was confirmed by treating i-uPA (5 nM) with Spectrozyme uPA chromogenic substrate (0.125 mM in distilled water) and monitoring (Spectramax Plus 384: Molecular Devices plate reader) for absence of colour development at 405 nM.
Flow Cytometry Assays.
U-937 cells in log phase growth were re-suspended in cold PBS/BSA at 1 x 10 6 cells.mL Cell surface-bound HMW-uPA activity was measured using the fluorogenic substrate Z-Gly-Gly-Arg-AMC. Fluorescence observed in this assay is directly proportional to cell-bound HMW-uPA activity due to the high specificity of the substrate for HMW-uPA. 33 The excitation wavelength range of the substrate is 365-380 nm and the emission wavelength range is 430-460 nm. PMA stimulated cells were allowed quantitative interpretation of fluorescence data and was generated using the linear region of a graph where fluorescence was plotted against time.
IC 50 Determinations.
The IC 50 values (concentration (nM) required to inhibit 50% of uPA activity) were obtained by conducting a log transformation of the inhibitor concentrations. Data was normalised to a common scale, where 100% activity was equal to maximal uPA activity, indicated by the control samples containing HMW-uPA and substrate, but no antagonist. Values were calculated from logarithmic sigmoidal dose response curves using the variable slope parameter, generated from GraphPad Prism V.
5.01 software (GraphPad Software Inc.)
